IP Library Granted Patent US 8,435,946
Granted Patent B2
US 8,435,946 · App. 12/132,642 · Granted May 7, 2013

Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,435,946
App. No.
12/132,642
Granted
May 7, 2013
Kind
B2
Abstract

Solid pharmaceutical compositions and methods of their use suitable for the oral delivery of pharmacologically active agents, e.g. peptides, comprising a therapeutically-effective amount of a pharmacologically active agent; a crospovidone or povidone; and a delivery agent for said pharmacologically active agent are disclosed. The compositions utilize micronized forms of the delivery agent which provides enhanced bioavailability of pharmacologically active agents, particularly calcitonin.

Claims (19)

1. A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising

a. a pharmacologically active polypeptide agent;

b. pharmaceutically acceptable inactive excipients, and

c. a delivery agent of formula I for said pharmacologically active polypeptide agent

wherein

R 1 , R 2 , R 3 , and R 4 are independently hydrogen, —OH, —NR 8 R 7 , halogen, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy;

R 5 is a substituted or unsubstituted C 2 -C 16 alkylene, substituted or unsubstituted C 2 -C 16 alkenylene, substituted or unsubstituted C 1 -C 12 alkyl(arylene), or substituted or unsubstituted aryl(C 1 -C 12 alkylene); and

R 6 and R 7 are independently hydrogen, oxygen, or C 1 -C 4 alkyl; and hydrates, pharmaceutically acceptable salts and solvates thereof, wherein said delivery agent is in micronized form and has an average particle size of less than 10 microns.

2. The composition according to claim 1 wherein the pharmacologically active polypeptide agent is a calcitonin.

3. The composition according to claim 2 wherein the calcitonin is salmon calcitonin.

4. The composition according to claim 3 , wherein the delivery agent is selected from the group consisting of N-(5-chlorosalicyloyl)-8-aminocaprylic acid (5-CNAC), N-(10-[2-hydroxybenzoly]amino)decanoic acid (SNAD), N-(8-[2-hydroxybenzoyl]amino)caprylic acid (SNAC) and disodium salts thereof.

5. The composition according to claim 4 , wherein the delivery agent is selected from the group consisting of a disodium salt of 5-CNAC, a disodium salt of SNAD, and a disodium salt of SNAC.

6. The composition according to claim 5 , wherein the delivery agent is a disodium salt of 5-CNAC.

7. The composition according to claim 1 wherein said inactive excipients are selected from the group consisting of crospovidone and povidone.

8. The composition according to claim 1 further comprising a diluent.

9. The composition according to claim 8 wherein the diluent is microcrystalline cellulose.

10. The composition according to claim 1 further comprising a lubricant.

11. The composition according to claim 10 wherein the lubricant is magnesium stearate.

12. A method for enhancing the oral bioavailability of a pharmacologically active polypeptide agent, said method comprising administering to a patient in need of a pharmacologically active polypeptide agent, an effective amount of a pharmaceutical composition according to claim 1 .

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2022
From: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
To: NOVO NORDISK A/S
Reel/Frame 060352/0663 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2021
From: NOVARTIS AG
To: EMISPHERE TECHNOLOGIES, INC.
Reel/Frame 057768/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2021
From: EMISPHERE TECHNOLOGIES, INC.
To: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
Reel/Frame 056750/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 16, 2013
From: EMISPHERE TECHNOLOGIES, INC.; NOVARTIS AG
To: EMISPHERE TECHNOLOGIES, INC.; NOVARTIS AG
Reel/Frame 029640/0099 →